PMID- 12796378
OWN - NLM
STAT- MEDLINE
DCOM- 20040106
LR  - 20071115
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 9
IP  - 6
DP  - 2003 Jun
TI  - The t(14;18) is associated with germinal center-derived diffuse large B-cell 
      lymphoma and is a strong predictor of outcome.
PG  - 2133-9
AB  - The t(14;18) is present in a significant proportion of diffuse large B-cell 
      lymphomas (DLBCLs), however, the prognostic effect of the translocation and the 
      relationship with transformed follicular lymphoma remains controversial. To 
      clarify these uncertainties, interphase fluorescence in situ hybridization (FISH) 
      was used to determine the incidence of the t(14;18) in nodal DLBCL, and this was 
      correlated with BCL2 expression, germinal center (GC) immunophenotype, and 
      patient outcome. FISH was performed on paraffin-extracted nuclei from 137 de novo 
      nodal DLBCLs. Eighteen of 137 de novo DLBCLs were t(14;18) positive. The t(14;18) 
      was most commonly associated with the subset of DLBCLs that expressed a GC 
      phenotype, defined as CD10+, BCL6+ (GC-type DLBCL): positive in 14 of 47 (30%) 
      cases, compared with 4 of 89 (5%) in the non-GC group (Pearson's chi(2) = 28.4; P 
      < 0.0001). All cases with a translocation expressed BCL2 protein, however, 40 
      expressed BCL2 protein without a t(14;18). GC-type DLBCL patients with a t(14;18) 
      had a significantly worse survival compared with GC-type DLBCL patients without 
      the translocation (2-year survivals were 29 and 63%, respectively; P = 0.006). Of 
      the cases without the translocation, BCL2 protein expression did not affect 
      survival. In contrast, in the non-GC group of DLBCLs, BCL2 protein expression 
      reduced the 2-year overall survival from 64% in the BCL2-negative group to 38%, 
      with a median survival of 15.0 months (P = 0.02). In conclusion, the t(14;18) is 
      common in DLBCLs, particularly in GC-type DLBCLs, where the presence of the 
      translocation has a poor prognostic effect. BCL2 protein expression defines a 
      group of non-GC DLBCL patients with a poor prognosis.
FAU - Barrans, Sharon L
AU  - Barrans SL
AD  - HMDS, Academic Unit of Haematology and Oncology, Leeds General Infirmary, Leeds, 
      United Kingdom. sharonb@hmds.org.uk
FAU - Evans, Paul A S
AU  - Evans PA
FAU - O'Connor, Sheila J M
AU  - O'Connor SJ
FAU - Kendall, S Jane
AU  - Kendall SJ
FAU - Owen, Roger G
AU  - Owen RG
FAU - Haynes, Andrew P
AU  - Haynes AP
FAU - Morgan, Gareth J
AU  - Morgan GJ
FAU - Jack, Andrew S
AU  - Jack AS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - *Chromosomes, Human, Pair 14
MH  - *Chromosomes, Human, Pair 18
MH  - Germinal Center/*pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, B-Cell/*genetics/mortality
MH  - Lymphoma, Large B-Cell, Diffuse/*genetics/mortality
MH  - Proto-Oncogene Proteins c-bcl-2/analysis
MH  - Retrospective Studies
MH  - *Translocation, Genetic
EDAT- 2003/06/11 05:00
MHDA- 2004/01/07 05:00
CRDT- 2003/06/11 05:00
PHST- 2003/06/11 05:00 [pubmed]
PHST- 2004/01/07 05:00 [medline]
PHST- 2003/06/11 05:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 2003 Jun;9(6):2133-9.